{"groups":[{"description":"Lenalidomide 25 mg administered by mouth (PO) once daily (QD) until progressive disease or unacceptable toxicity","id":"FG000","title":"Lenalidomide"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"16"}],"type":"Progressive disease or Relapsed Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Nervous participant"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Serious Adverse Event Related"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"26"}],"type":"STARTED"},{"achievements":[{"comment":"Safety Population includes participants who received at least one dose of lenalidomide","groupId":"FG000","numSubjects":"26"}],"type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"26"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"This study included Japanese participants with relapsed or recurrent adult T-cell leukemia (ATL) who had previously received anti- ATL chemotherapy and who were categorized as having acute-lymphoma or unfavorable chronic-type ATL."}